The value of recombinant thrombomodulin in sepsis-induced coagulopathy was recently evaluated in a multinational, randomized controlled phase III trial (including patients with a platelet count < 50 × 109/L and a prothrombin time ratio > 1.4). The gene discussed is THBD; the disease is Sepsis.